Steven L. Hoerter is President and CEO of Deciphera Pharmaceuticals. Prior to joining Deciphera, Mr. Hoerter was Chief Commercial Officer at Agios Pharmaceuticals, Inc. where he built and led the team responsible for the commercialization of the company’s portfolio of first-in-class medicines for oncology and rare genetic diseases. Prior to joining Agios in 2016, Mr. Hoerter was Executive Vice President and Chief Commercial Officer at Clovis Oncology, Inc. Before joining Clovis, Mr. Hoerter was General Manager and Management Center Head at Roche for the Sub-Saharan Africa and Indian Ocean Region. From 2005 to 2010, he held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business. Prior to that, Mr. Hoerter held commercial roles at Chiron Corporation and Eli Lilly and Company in the U.S., Europe, and Africa. Mr. Hoerter currently serves on the Board of Directors at Constellation Pharmaceuticals, a biotechnology focused on developing novel therapeutics for patients with cancers associated with abnormal gene expression and was previously a member of the Board of Directors of Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, until the company’s acquisition by Roche in 2017. Mr. Hoerter received his B.A. from Bucknell University, M.B.A. from Tilburg University in the Netherlands and M.S. in management from Purdue University.
Daniel L. Flynn, Ph.D. is CSO and Founder of Deciphera Pharmaceuticals. Before founding Deciphera in 2003, Dr. Flynn held senior roles in small molecule chemistry with various biotechnology and pharmaceuticals companies, including as Senior Director of Chemistry with Millennium Pharmaceuticals, Director, Medicinal Chemistry at Amgen Inc., and Director of Medicinal Chemistry, Combinatorial Chemistry and Research Fellow at Monsanto Company, G.D. Searle Unit. Dr. Flynn is currently Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence and has served as the national Chair for the Division of Medicinal Chemistry of the American Chemical Society. Dr. Flynn received both his Ph.D. in medicinal chemistry and his B.S. in pharmacy from the University of Kansas, and he completed post-doctorate training in synthetic organic chemistry at Indiana University.
Jeff Held is General Counsel of Deciphera Pharmaceuticals. Prior to joining Deciphera, Mr. Held was General Counsel at another public biotechnology company. Mr. Held has also served in senior legal positions, and built the legal function, at several Boston-based life science and technology companies. Mr. Held spent the first part of his career at law firms in New York and Boston as a corporate lawyer specializing in counseling high-growth companies. Mr. Held earned a JD from Fordham University School of Law and a BA, cum laude, from Tufts University.
Tucker Kelly is Chief Financial Officer of Deciphera Pharmaceuticals. Prior to joining Deciphera, Mr. Kelly served as Chief Financial Officer of AdvanDx, Inc., a private molecular diagnostics company, from 2012 to 2014. Prior to joining AdvanDx, Mr. Kelly served as chief financial officer for various public and private life science companies, including deCODE genetics, Inc. from 2010 to 2011 and Critical Therapeutics, Inc. from 2007 to 2008. Prior to joining Critical Therapeutics, Mr. Kelly was a life sciences investment banker at Robertson Stephens and Canaccord Adams and was an attorney in the corporate and securities group of Foley, Hoag and Elliot, LLP. Mr. Kelly holds a Juris Doctor with honors degree from the University of Chicago Law School and a Bachelor of Science in Foreign Services degree cum laude from the Georgetown University School of Foreign Service.
Peter Lasky is Vice President of Human Resources at Deciphera Pharmaceuticals. Mr. Lasky has more than 25 years of human resources leadership experience within the pharmaceutical, biotechnology and medical device industry. Prior to joining Deciphera, he served as Senior Vice President, Global Human Resources at Wave Life Sciences where he established the organization’s human resources function. Mr. Lasky also served as Senior Vice President, Global Human Resources at Shire Pharmaceuticals where he was responsible for setting the strategic direction of the human resources function and leading a global team for this multi-national commercial-stage pharmaceutical company. During his career Mr. Lasky, who has always focused on being a strategic business partner dedicated to creating an innovative work environment, held human resources leadership positions at AstraZeneca, Millipore Corporation and Genetics Institute (Wyeth). Peter holds a BS in Business Administration and Industrial Management from State University New York at Plattsburgh. He has also completed various postgraduate courses and programs at the Wharton School, University of Pennsylvania, Darden School University of Virginia and Cornell University. Mr. Lasky speaks at various industry conferences on a wide range of human resources-related topics and has served on several advisory boards including the National Science Foundation Council on Bio- manufacturing education and the Massachusetts Biotechnology Council.
Daniel C. Martin is Chief Commercial Officer at Deciphera Pharmaceuticals. Mr. Martin has more than 20 years of commercial experience within the biopharmaceutical industry with extensive background in oncology, including immuno-oncology. Prior to joining Deciphera, he served as Senior Vice President, Commercial at Heron Therapeutics where he built the company’s commercial organization, including establishing marketing, sales, and market access functions, and launched its oncology portfolio. Mr. Martin also served as commercial lead for Heron’s portfolio strategy and new product planning across all therapeutic areas. Before joining Heron, Mr. Martin held commercial leadership positions at Dendreon and at Amgen, where he played lead roles in multiple U.S. and global oncology launches. Earlier in his career, Mr. Martin was a management consultant with Deloitte Consulting where he advised global biopharmaceutical companies in commercial strategy and operations. Mr. Martin received his undergraduate degree with honors in economics and biology from the University of Virginia and an MBA from the Wharton School at the University of Pennsylvania.
Christopher J. Morl is Chief Business Officer of Deciphera Pharmaceuticals. Mr. Morl has more than 25-years of experience in strategic and operational roles in private biotechnology and multinational pharmaceutical companies. Prior to joining Deciphera, Mr. Morl was a member of the senior executive team at miRagen Therapeutics, Inc., an oligonucleotide therapeutics discovery and development company, serving as the Chief Operating Officer from May 2016 to October 2016 and Chief Business Officer from May 2013 to May 2016. Prior to joining miRagen, Mr. Morl served in senior management roles at various biotechnology companies, including as Chief Operating Officer at Ambit Biosciences Corporation, an oncology-focused biotechnology company engaged in discovering and developing targeted small molecule kinase inhibitors, and as Vice President of Business Development at Agensys, Inc., prior to and following the acquisition of Agensys Inc. by Astellas Pharma, Inc. Before joining Agensys, he served for 20 years in positions of increasing responsibility in research, sales, marketing, business development and county/general management at GlaxoSmithKline plc. From February 2010 to December 2016, Mr. Morl served as an Independent Director of Alethia Biotherapeutics. Mr. Morl earned a B.Sc. (Hons) in Applied Biology and Pharmacology from the University of London (UK) and an M.B.A. from Cranfield School of Management (UK).
Jama Pitman is Vice President of Regulatory and Quality Assurance at Deciphera Pharmaceuticals. Ms. Pitman joined Deciphera in January 2015 and has over 18 years of industry experience. She has successfully led regulatory teams in supporting Phase 1 to Phase 3 drug development programs at both emerging biotechnology and established pharmaceutical companies. She has contributed to drug development programs intended to provide new therapeutic options to patients with cancer, including, multiple myeloma, prostate cancer, thyroid cancer, and ovarian cancer. Additionally, she has been a key contributor to the development of drugs to treat patients with non-oncology diseases such as Hepatitis B and C, Hereditary Angioedema, Fabry Disease, Hunter’s Syndrome, and Gaucher’s Disease. Ms. Pitman received her B.S. degree in Microbiology from the University of New Hampshire.
Stephen B. Ruddy, Ph.D. is Chief Technical Officer of Deciphera Pharmaceuticals. Dr. Ruddy has more than 25 years of global pharmaceutical management and leadership experience in small-molecule and biologics development and manufacturing. Prior to joining Deciphera, he served as Vice President of Pharmaceutical Development at TESARO, Inc., an oncology-focused biopharmaceutical company, where he built and led a CMC organization that enabled multiple small-molecule NDA and MAA approvals and advanced multiple biologic immuno-oncology product candidates from discovery into clinical development. Before joining TESARO, Dr. Ruddy served as Senior Director, Technology Development & Operations at ViroPharma Inc., which was later acquired by Shire plc. Prior to joining ViroPharma, he served in CMC leadership roles of increasing responsibility at Elan Corporation plc, Merck & Co., Inc., NanoSystems LLC and Sterling Winthrop Pharmaceuticals. Dr. Ruddy earned a B.S. in Pharmacy and a Ph.D. in Pharmaceutics, both from the University of North Carolina at Chapel Hill.